Topical 1% cidofovir for the treatment of basal cell carcinoma

European Journal of Dermatology

Volumn 12, Issue 6, 2002, Pages 562-564

  Calista, Donato ^a  

^a BUFALINI HOSPITAL   (Italy)

Author keywords

Basal cell carcinoma; Cidofovir; Topical therapy

Indexed keywords

CIDOFOVIR; COSMETIC;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; SKIN BIOPSY; TREATMENT OUTCOME; WOUND HEALING;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; CARCINOMA, BASAL CELL; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; SAMPLING STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036860265     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. MacKie RM. Epidermal skin tumours. In: Rook A, Wilkinson DS, Ebling FJG. Textbook of Dermatology. Champion RH, Burton JL, Burns DA Breathnach SM, eds. Blackwell Science Inc 6th ed. 1998: 1691-2.
2. Wennberg AM. Basal cell carcinoma: New aspects of diagnosis and treatment. Acta Derm Venereol (Stockh) 2000; 209 (suppl.): 5-25.
3. Orenberg EK, Miller BH, Greenway HT, Koperski JA, Lowe N, Rosen T, et al. The effects of intralesional 5-Fluorouracil therapeutic implant MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol 1992; 27: 723-8.
4. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
5. Vander Straten M, Lee P, Weitzul S, Cockerell CJ, Tyring SK. Advances in the treatment of basal cell carcinoma: The promise of pharmacologic therapy. Adv Dermatol 2000; 16: 299-318.
6. Beutner KR, Geisse JK, Helmann D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinomas to the immune response modifier imiquimod 5%. J Am Acad Dermatol 1999; 41: 1002-7.
7. Zabawski EJ, Cockerell CJ. Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998; 39: 741-5.
8. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000; 60: 205-9.
9. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol 1995; 45: 230-5.
10. Pranky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolarynqol Neck Surg 1999; 125: 1143-8.
11. Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg 2001; 63: 93-12.
12. Fife K, Gill J, Bourboulia D, Gazzard B, Nelson M, Bower M. Cidofovir for the treatment of Kaposi's sarcoma in an HIV negative homosexual man. Br J Dermatol 1999; 141: 1148-9.
13. Murono S, Raab-Traub N, Pagano JS. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res 2001; 161: 7875-7.
14. Calista D, Riccioni L, Coccia L. Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir. Br J Ophthalm 2002; 86; 932-3.
15. Redondo P, Idoate M, Galofre JC, Solano T. Cidofovir inhibits growth of B16 melanoma cells in vivo. Br J Dermatol 2000; 143: 741-8.
16. DeClercq E, Andrei G, Balzarini J, Hatse S, Liekens S, Naesens L, et al. Antitumor potential of acyclic nucleoside phosphonates. Nucleosides Nucleotides 1999; 18: 759-71.
17. Liekens S, Andrei G, Vandeputte M, De Clercq E, Neyts J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res 1998; 58: 2562-7.
18. Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res 2001; 61: 5057-64.
19. Calista D. Topical cidofovir for erythroplasia of Queyrat of the glans penis. Br J Dermatol 2002; 147: 399.